argenex SE $ARGX Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. decreased its position in shares of argenex SE (NASDAQ:ARGX) by 22.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,466 shares of the company’s stock after selling 2,218 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in argenex were worth $7,159,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Guardian Partners Inc. acquired a new stake in argenex in the third quarter worth $863,000. Sowell Financial Services LLC boosted its position in shares of argenex by 25.8% during the third quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock worth $440,000 after purchasing an additional 94 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of argenex by 59.4% during the third quarter. Pinnacle Associates Ltd. now owns 757 shares of the company’s stock worth $726,000 after purchasing an additional 282 shares in the last quarter. Diversify Advisory Services LLC boosted its position in shares of argenex by 32.5% during the third quarter. Diversify Advisory Services LLC now owns 2,911 shares of the company’s stock worth $2,791,000 after purchasing an additional 714 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new position in shares of argenex in the 3rd quarter valued at $236,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the topic of several research analyst reports. DZ Bank reaffirmed a “buy” rating on shares of argenex in a research note on Friday, October 9th. Sanford C. Bernstein reiterated a “buy” rating on shares of argenex in a report on Thursday, October 8th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Bank of America boosted their target price on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Finally, Royal Bank Of Canada lowered their price target on argenex from $1,100.00 to $1,025.00 and set an “outperform” rating for the company in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,148.00.

argenex Stock Down 1.6%

argenex stock opened at $875.76 on Friday. The stock has a market capitalization of $55.08 billion, a PE ratio of 33.63, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75. The company has a 50 day moving average of $956.17 and a 200-day moving average of $885.45.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a net margin of 32.19% and a return on equity of 43.59%. The company had revenue of $1.75 billion during the quarter. Equities analysts anticipate that argenex SE will post 28.71 EPS for the current fiscal year.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.